ReviewInternational journal of nanomedicine2010
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.
Review in International journal of nanomedicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 34 citations in OpenAlex.
- Liposomal factor VIII as an efficient pharmaceutical system for the treatment of hemophilia.Iranian journal of basic medical sciences · 2024Article
- Lipid-engineered nanotherapeutics for cancer management.Frontiers in pharmacology · 2023Review
- Curcumin Encapsulated PEGylated Nanoliposomes: A Potential Anti-Infective Therapeutic Agent.Indian journal of microbiology · 2019Article
- Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, EloctateJournal of blood medicine · 2016Review
- Effects of nanoliposomal and pegylated nanoliposomal artemisinin in treatment of breast cancer.Indian journal of clinical biochemistry : IJCB · 2014Article
- Recent developments in protein and peptide parenteral delivery approaches.Therapeutic delivery · 2014Article
- In vitro evaluation of the efficacy of liposomal and pegylated liposomal hydroxyurea.Indian journal of clinical biochemistry : IJCB · 2014Article
- Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.Journal of controlled release : official journal of the Controlled Release Society · 2013Review
- Study of toxicity effect of pegylated nanoliposomal artemisinin on breast cancer cell line.Indian journal of clinical biochemistry : IJCB · 2013Article
- Modeling and prediction of cytotoxicity of artemisinin for treatment of the breast cancer by using artificial neural networks.SpringerPlus · 2013Article
- Animal models of hemophilia.Progress in molecular biology and translational science · 2012Review
- Liposomes bearing fibrinogen could potentially interfere with platelet interaction and procoagulant activity.International journal of nanomedicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophilia A is a rare X-linked bleeding disorder caused by lack or dysfunction of coagulation factor VIII (FVIII). Hemophilia A is treated with replacement therapy, but frequent injections of the missing FVIII often lead to the formation of inhibitory antibodies. Patients who develop high levels of inhibitors must be treated with bypassing agents such as activated FVII (FVIIa). Both FVIII and FVIIa have short half-lives and require multiple injections. Long-acting forms of these proteins would therefore reduce the frequency of injections, improve patient compliance and reduce complications. In this article we present a new platform technology that produces long-acting forms of FVIII and FVIIa and improves the efficacy of hemophilia treatment. This technology is based on the binding of proteins/peptides to the outer surface of PEGylated liposomes (PEGLip). Binding is dependent on an amino acid consensus sequence within the proteins and is highly specific. At the same time, binding is non-covalent and does not require any modification of the therapeutic agent or its production process. Association of proteins with PEGLip results in substantial enhancements in their pharmacodynamic properties following administration. These improvements seem to arise from the association of formulated proteins with platelets prior to induction of coagulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.